INVA
Innoviva, Inc.
NASDAQ · Healthcare · Biotechnology · US
$21.08
+1.44%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$20.73
From 52W high−13.04%
Volume590512.00
Market cap$1.52B
P/E (TTM)4.3x
P/S (TTM)3.4x
Div yield—
Key dataOct 19, 2026
Open
$20.73
From 52W high
−13.04%
Volume
590512.00
Market cap
$1.52B
ValuationView details →
P/E (Fwd)
9.6x
EV/EBITDA
1.6x
P/E (TTM)
4.3x
RSI (14)
52.9
MomentumView details →
1D Return
+1.44%
YTD Return
+5.80%
SummaryUpdated Jun 1, 2026
Innoviva, Inc. (NASDAQ:INVA) is a biotechnology company founded in 1996 and headquartered in Burlingame, California. Originally incorporated as Theravance, Inc., the company changed its name to Innoviva in January 2016. The company specializes in developing and commercializing pharmaceutical products for respiratory diseases, particularly chronic obstructive pulmonary disease (COPD) and asthma. Innoviva operates through a strategic partnership model, most notably with pharmaceutical giant GlaxoSmithKline, to bring respiratory medications to market globally.
Similar companies
Latest newsMore news →
Gilead Sciences said it will present 28 research presentations, including two oral presentations, at Innoviva, Inc. 2026 on HIV treatment, prevention, and emerging antiviral programs.12h agoInnoviva reported Q2 2026 earnings of $0.59 per share, beating the Zacks Consensus Estimate of $0.56 per share, and compared to $0.77 per share a year ago.75d ago